Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. (Operator Instructions) I would now like to ...

US biotech major Amgen presented its fourth quarter and 2024 financial results late Tuesday, along with its guidance for 2025.